Early experience with convalescent plasma as immunotherapy for COVID-19 in China: Knowns and unknowns
Early experience with convalescent plasma as immunotherapy for COVID-19 in China: Knowns and unknowns
复制标题
中国使用恢复期血浆作为 COVID-19 免疫疗法的早期经验：已知和未知。
DOI：
10.1111/vox.12968
复制
发表时间：
2020-08-01
期刊：
影响因子：
2.7
通讯作者：
Xia, Rong
中科院分区：
文献类型：
--
作者：
Chen, Binzhen;Xia, Rong
背景和目的在冠状病毒病（COVID-19）缺乏疫苗或特定药物治疗选择的情况下，中国的注意力已转移到恢复期血浆的可能治疗用途上。COVID-19恢复期血浆（CCP）目前正在研究中。我们根据中国COVID-19恢复期血浆临床治疗指南总结了截至2020年5月5日关于CCP治疗的临床研究和其他研究数据，以及浙江大学附属第一医院的临床经验，作为全面抗疫策略的一部分。材料与方法截至2020年5月5日，当疫情在中国得到良好控制时，检索并审查了与恢复期血浆相关的医疗保健数据库和英文文献来源。确定了临床和方法学异质性的来源。结果截至2020年5月5日，在中国各地收集了多达2000份CCP样本，并对700名COVID-19患者进行了接种。每次献血时从献血者中收集200-400 ml血浆，抗体滴度> 1：160。我们确定了中国的三项COVID-19临床研究。分析显示，与未经治疗的病例相比，临床结局有统计学显著改善（P < 0.001）。未报告任何不良反应。结论从初步研究来看，恢复期血浆治疗对COVID-19有效且安全。然而，显然需要设计良好的随机对照试验（RCT）或其他正式研究来进一步评估CCP的疗效和任何潜在的不良反应。
Background and objectives In the absence of a vaccine or specific drug treatment options for coronavirus disease (COVID-19), attention has been shifted in China to the possible therapeutic use of convalescent plasma. COVID-19 convalescent plasma (CCP) is currently under investigation. We summarized clinical studies and other research data available as of 5 May 2020 on CCP therapy according to theClinical Treatment Guideline of COVID-19 Convalescent Plasmain China, as well as clinical experience at the First Affiliated Hospital of Zhejiang University, as part of a comprehensive anti-epidemic strategy. Materials and methods As of 5 May 2020, when the epidemic was well-controlled in China, healthcare databases and sources of English literature relating to convalescent plasma were searched and reviewed. Sources of clinical and methodological heterogeneity were identified. Results As of 5 May 2020, up to 2000 samples of CCP had been collected across China and administered to 700 COVID-19 patients. From donors, 200-400 ml of plasma was collected at each donation, with antibody titres > 1:160. We identified three clinical studies for COVID-19 in China. Analyses showed a statistically significant improvement in clinical outcomes compared with untreated cases (P < 0.001). No adverse effects were reported. Conclusion From initial studies, convalescent plasma therapy appears effective and safe for COVID-19. However, there is clearly a need for well-designed RCTs (randomized controlled trials) or other formal studies to further evaluate the efficacy and any potential adverse effects of CCP.